Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine

AIDS

Volumn 21, Issue 15, 2007, Pages 2077-2082

  Flys, Tamara S ^a   Mwatha, Anthony ^b   Guay, Laura A ^a   Nakabiito, Clemensia ^c   Donnell, Deborah ^b   Musoke, Philippa ^c   Mmiro, Francis ^c   Jackson, J Brooks ^a   Eshleman, Susan H ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c MAKERERE UNIVERSITY   (Uganda)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Africa; HIV drug resistance; Nevirapine; Women

Indexed keywords

NEVIRAPINE; PROTEIN K103N; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; BIOASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EXPOSURE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MUTATIONAL ANALYSIS; POINT MUTATION; PREGNANCY; PRIORITY JOURNAL; REPEATED DRUG DOSE; SAMPLING; SEROTYPE; SINGLE DRUG DOSE; TREATMENT RESPONSE; UGANDA; VERTICAL TRANSMISSION; VIRUS LOAD;

DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; UGANDA; VIRAL LOAD;

EID: 34648813696     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282703847     Document Type: Article

References (19)

1. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-infant transmission of HIV-1 in Kampala, Uganda: HIVNET-012 randomised trial. Lancet 1999; 354:795-802.
2. Jackson JB, Musoke P, Fleming T, Guay L, Bagenda D, Allen M, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18 months follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362:859-868.
3. McIntyre J. Preventing mother-to-child transmission of HIV: successes and challenges. BJOG 2005; 112:1196-1203.
4. Jackson JB, Becker-Pergola G, Guay L, Musoke P, Mracna M, Fowler MG, et al. Identification of the K103N mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000; 14:FT111-FT115.
5. Eshleman SH, Guay LA, Mwatha A, Brown E, Cunningham SP, Musoke P, et al. Characterization of nevirapine (NVP) resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single dose NVP (HIVNET 012). J Acquir Immune Defic Syndr 2004; 35:126-130.
6. Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, et al. Nevirapine (NVP) resistance in women with subtype C, compared to subtypes A and D, after administration of single-dose NVP. J Infect Dis 2005; 192:30-36.
7. Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, et al. Sensitive drug resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after single dose NVP: HIVNET 012. J Infect Dis 2005; 192:24-29.
8. Flys TS, Donnell D, Mwatha A, Nakabiito C, Musoke P, Mmiro F, et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis 2007; 195:711-715.
9. Church JD, Jones D, Flys T, Hoover DR, Marlowe N, Chen S, et al. Sensitivity of the ViroSeq HIV-1 Genotyping System for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagnostics 2006; 8:420-422.
10. Flys TS, Chen S, Jones DC, Hoover DR, Church JD, Fiscus SA, et al. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single dose nevirapine in women with HIV-1 subtypes A, C and D. J Acquir Immune Defic Syndr 2006; 42:61-63.
11. Collins JA, Thompson MG, Paintsil E, Ricketts M, Gedzior J, Alexander L. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J Virol 2004; 78:603-611.
12. Palmer S, Boltz V, Maldarelli F, Kearney M, Halvas EK, Rock D, et al. Selection and persistence of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping nonnucleoside therapy. AIDS 2006; 20:701-710.
13. Eure C, Bakaki P, McConnell M, Mubiru M, Thigpen M, Musoke P, et al. Effectiveness of repeat single-dose nevirapine in subsequent pregnancies among Ugandan women. Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006.
14. Martinson N, Ekouevi D, Gray G, Tonwe-Gold B, Dhlamini P, Veroy V, et al. Effectiveness of single-dose nevirapine in consecutive pregnancies in Soweto and Abidjan. Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006.
15. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-240.
16. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-147.
17. Coovadia H, Marais B, Abrams E, Sherman G, Barry G, Hammer S, et al. Virologic responses to NNRTI treatment among women who took single-dose nevirapine 18 to 36 months earlier. Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006.
18. Zijenah L, Kadzirange G, Rusakaniko S, Kufa T, Matsikire E, Moyo S, et al. Community-based generic ART following single-dose nevirapine or short-course zidovudine in Zimbabwe. Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006.
19. McConnell MS, Stringer JSA, Kourtis AP, Weidle PJ, Eshleman SH. Use of single dose nevirapine for prevention of mother to child transmission of HIV-1: Does development of resistance matter? Am J Obstet Gynecol 2007; in press.